Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results
Caroline Mollévi(Inserm), Amélie Anota(Centre Léon Bérard), Célia Touraine(Université de Montpellier), Sophie Gourgou(Université de Montpellier), William Jacot(Inserm), Franck Bonnetain(Azienda Ospedaliera Universitaria Pisana), Hélène de Forges(Université de Montpellier), C. Bourgier(Inserm), Béata Juzyna(UniCancer Group), Mohamed Hebbar, Antoine Barbieri(Inserm), Bruno Chauffert(Centre Hospitalier de Saint-Quentin), Thierry Conroy(Inserm)
Cited by 18
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
|Journal of Clinical Oncology|2011|2.1k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k